The role of ramucirumab with docetaxel in epidermal growth factor receptor mutant and wild-type non-small cell lung cancer

BACKGROUND: Ramucirumab paired with docetaxel extends progression free survival and overall survival in non-small cell lung cancer (NSCLC) following progression on platinum therapy. There is some data that epidermal growth factor receptor (EGFR) mutant disease would respond better to vascular endoth...

Descripción completa

Detalles Bibliográficos
Autores principales: Ellis-Caleo, Tim, Neal, Joel W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411152/
https://www.ncbi.nlm.nih.gov/pubmed/34527325
http://dx.doi.org/10.21037/jtd-21-557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411152/
https://www.ncbi.nlm.nih.gov/pubmed/34527325
http://dx.doi.org/10.21037/jtd-21-557

Ejemplares similares